Literature DB >> 15709001

Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Marlén M I Aasa-Chapman1, Sophie Holuigue, Keith Aubin, Mailee Wong, Nicola A Jones, David Cornforth, Pierre Pellegrino, Philippa Newton, Ian Williams, Persephone Borrow, Aine McKnight.   

Abstract

Specific CD8 T-cell responses to human immunodeficiency virus type 1 (HIV-1) are induced in primary infection and make an important contribution to the control of early viral replication. The importance of neutralizing antibodies in containing primary viremia is questioned because they usually arise much later. Nevertheless antienvelope antibodies develop simultaneously with, or even before, peak viremia. We determined whether such antibodies might control viremia by complement-mediated inactivation (CMI). In each of seven patients studied, antibodies capable of CMI appeared at or shortly after the peak in viremia, concomitantly with detection of virus-specific T-cell responses. The CMI was effective on both autologous and heterologous HIV-1 isolates. Activation of the classical pathway and direct viral lysis were at least partly responsible. Since immunoglobulin G (IgG)-antibodies triggered the CMI, specific memory B cells could also be induced by vaccination. Thus, consideration should be given to vaccination strategies that induce IgG antibodies capable of CMI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709001      PMCID: PMC548453          DOI: 10.1128/JVI.79.5.2823-2830.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18).

Authors:  Zsuzsa Bajtay; Cornelia Speth; Anna Erdei; Manfred P Dierich
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

2.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.

Authors:  M Larsson; X Jin; B Ramratnam; G S Ogg; J Engelmayer; M A Demoitie; A J McMichael; W I Cox; R M Steinman; D Nixon; N Bhardwaj
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

Review 3.  Immunoglobulin G: functional sites.

Authors:  D R Burton
Journal:  Mol Immunol       Date:  1985-03       Impact factor: 4.407

4.  Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis.

Authors:  G T Spear; B L Sullivan; A L Landay; T F Lint
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.

Authors:  G Pantaleo; J F Demarest; H Soudeyns; C Graziosi; F Denis; J W Adelsberger; P Borrow; M S Saag; G M Shaw; R P Sekaly
Journal:  Nature       Date:  1994-08-11       Impact factor: 49.962

7.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Development of HIV-1 group-specific neutralizing antibodies after seroconversion.

Authors:  A McKnight; P R Clapham; J Goudsmit; R Cheingsong-Popov; J N Weber; R A Weiss
Journal:  AIDS       Date:  1992-08       Impact factor: 4.177

Review 10.  The relevance of complement to virus biology.

Authors:  Clare E Blue; O Brad Spiller; David J Blackbourn
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  44 in total

1.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

3.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

4.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

Review 5.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

6.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

7.  An antibody-recruiting small molecule that targets HIV gp120.

Authors:  Christopher G Parker; Robert A Domaoal; Karen S Anderson; David A Spiegel
Journal:  J Am Chem Soc       Date:  2009-11-18       Impact factor: 15.419

8.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.